Clinical trials: Recurrent, Persistent or Metastasized Cervical Cancer, open to volunteers
Cervical Cancer
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer.
- Trial name
- NCT05817214
- Testing
- Cadonilimab, Anlotinib, Granulocyte-Macrophage Colony-Stimulating Factor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhongnan Hospital